Endocyte stock: buy or sell?
December 20th, 2018
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States.
Should I buy Endocyte stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, 2 buy setups match with Endocyte stock now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Endocyte stock a buy?
Banks and financial institutions post stock ratings everyday.Unfortunately, we couldn't find any rating for ECYT stock for the last 30 days.
Endocyte stock analysis
Despite of closing lower ($23.99, -0.04%), Endocyte marked new all time high at $24.00.
Despite of the negative close ($23.99, -0.04%), Endocyte topped new all time high at $24.00. ECYT shows a sign of strength in the short-term after finally breaking out above $23.94 on December and marking a new rising bottom. Since price and SMA100d lines crossed up , ECYT climbed $8.43 (54.18%).
Endocyte ended this week at $23.99 after topping to a new all time high ($24.00) and appreciated a tiny 0.63%. Counting this, it's been 4 climbing weeks in a row, soaring a 1.65%.
Endocyte stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. By mid October 2018 ECYT price bounced up over the SMA of 20 weeks that acted as support stopping new slides.
Endocyte stock price history
Endocyte stock went public on March 5th, 2018 with a price of $6.391. Since then, ECYT stock surged a 275.40%, with an average of 275.40% per year. If you had invested right after ECYT's IPO a $1,000 in Endocyte stock in 2018, it would worth $2,754.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Endocyte stock historical price chart
ECYT stock reached all-time highs on December with a price of $24.00.
Endocyte stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we have not detected any price prediction for Endocyte stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareOn November, Endocyte reported its latest financial data, posting a decent climb for the Earnings per Share (EPS). Analyst were expecting $-0.16 per share, but Endocyte posted $-0.17.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2016, last anual revenues report draw a neutral movement of 0.00% to $0.07 million dollars. By contrast, its earnings margin (compared to sales) collapsed to -78,663.14%, that is $-55.06 million. To have an up to date view of the financial situation of Endocyte, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2018-Q3 that can be compared to 2017 fiscal year results. Annual Endocyte TTM sales up to September 2018 were $0.13 and income was $-41.34 million USD. When comparing this TTM figures with the last reported annuality, we can review Endocyte business evolution since December 2017: Annual sales up to September, compared to lastest yearly report, rocketed an astounding 83.82%. Aligned with this, profit margin (net income/sales) climbed at -78,663.14%.
|2013||$65 M||-||$-18.03 M-27.8%||-|
|2014||$70 M||8.45%||$5.46 M7.8%||-130.28%|
|2015||$0.07 M||-99.90%||$-41.27 M-58956.7%||-855.93%|
|2016||$0.07 M||0.00%||$-43.89 M-62696.6%||6.34%|
|2017||$0.07 M||0.00%||$-55.06 M-78663.1%||25.47%|
|TTM||$0.13 M||83.82%||$-41.34 M-32126.5%||-24.93%|
Quarterly financial resultsEndocyte posted $0.09 M in sales for 2018-Q3, a 493.54% up compared to previous quarter. Reported quarter earnings marked $-12.61 million with a profit margin of -14,684.64%. Profit margin rocketed a 65,264.20% compared to previous quarter when profit margin was -79,948.84%. When comparing revenues to same quarter last year, Endocyte sales marked a dazzling gain and climbed a 164.17%.
|2016-Q4||$0.01 M||-||$-11.07 M-92250.0%||-|
|2017-Q1||$0.01 M||4.17%||$-11.49 M-91920.0%||3.79%|
|2017-Q2||$0.01 M||0.00%||$-11.74 M-93920.0%||2.18%|
|2017-Q3||$0.03 M||160.00%||$-23.27 M-71590.2%||98.18%|
|2017-Q4||$0.01 M||-61.54%||$-8.56 M-68512.2%||-63.19%|
|2018-Q1||$0.02 M||26.84%||$-8.60 M-54258.3%||0.45%|
|2018-Q2||$0.01 M||-8.77%||$-11.56 M-79948.8%||34.43%|
|2018-Q3||$0.09 M||493.54%||$-12.61 M-14684.6%||9.02%|
Endocyte ownershipWhen you are planning to invest in shares of a stock, it's worth to check its ownership structure.
Endocyte shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a of all shares.
The following table compares ownership indicators for other stocks related to Endocyte:
|Market cap||$0.0 M|
|Total shares||0.0 M|
|Float shares||0.0 M|
|- Institutional holdings (%)||0.0%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Thursday, December 20th, 2018|
|Day range||$23.99 - $24.00|
|Average true range||$0.09|
|50d mov avg||$22.67|
|100d mov avg||$20.08|
|200d mov avg||$0.00|
Endocyte performanceTo better understand Endocyte performance you must becnhmark its gains with other related stocks in same sector or industry. We compared Endocyte against in the following table: